NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018

Restricted access

The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for SCLC regarding immunotherapy, systemic therapy, and radiation therapy. For the 2018 update, new sections were added on “Signs and Symptoms of SCLC” and “Principles of Pathologic Review.”

Provided content development and/or authorship assistance.

Please Note

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. The NCCN Guidelines® Insights highlight important changes in the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further understanding of these changes by summarizing salient portions of the panel's discussion, including the literature reviewed.

The NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.

The full and most current version of these NCCN Guidelines is available at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

  • 1.

    Noone A, Howlader N, Krapcho M. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Available at: https://seer.cancer.gov/csr/1975_2015/.

    • Search Google Scholar
    • Export Citation
  • 2.

    Govindan R, Page N, Morgensztern D. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 2006;24:45394544.

    • Search Google Scholar
    • Export Citation
  • 3.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:730

  • 4.

    Pesch B, Kendzia B, Gustavsson P. Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 2012;131:12101219.

    • Search Google Scholar
    • Export Citation
  • 5.

    Leone FT, Evers-Casey S, Toll BA, Vachani A. Treatment of tobacco use in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e61S77S.

    • Search Google Scholar
    • Export Citation
  • 6.

    Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e142S165S.

    • Search Google Scholar
    • Export Citation
  • 7.

    Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e400S419S.

    • Search Google Scholar
    • Export Citation
  • 8.

    Yu JB, Decker RH, Detterbeck FC, Wilson LD. Surveillance Epidemiology and End Results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 2010;5:215219.

    • Search Google Scholar
    • Export Citation
  • 9.

    Kalemkerian GP. Advances in the treatment of small-cell lung cancer. Semin Respir Crit Care Med 2011;32:94101.

  • 10.

    Amini A, Byers LA, Welsh JW, Komaki RU. Progress in the management of limited-stage small cell lung cancer. Cancer 2014;120:790798.

  • 11.

    Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010;35:202215.

    • Search Google Scholar
    • Export Citation
  • 12.

    Travis W, Brambilla E, Burke A. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th edition. Geneva, Switzerland: World Health Organization; 2015.

    • Search Google Scholar
    • Export Citation
  • 13.

    Travis WD, Brambilla E, Burke AP. Introduction to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol 2015;10:12401242.

    • Search Google Scholar
    • Export Citation
  • 14.

    Travis WD, Brambilla E, Nicholson AG. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015;10:12431260.

    • Search Google Scholar
    • Export Citation
  • 15.

    Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol 2010;21(Suppl 7):vii6571.

  • 16.

    Zakowski MF. Pathology of small cell carcinoma of the lung. Semin Oncol 2003;30:38.

  • 17.

    Nicholson SA, Beasley MB, Brambilla E. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002;26:11841197.

    • Search Google Scholar
    • Export Citation
  • 18.

    Pignon JP, Arriagada R, Ihde DC. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:16181624.

  • 19.

    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890895.

    • Search Google Scholar
    • Export Citation
  • 20.

    Turrisi AT III, Kim K, Blum R. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265271.

    • Search Google Scholar
    • Export Citation
  • 21.

    Faivre-Finn C, Snee M, Ashcroft L. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017;18:11161125.

    • Search Google Scholar
    • Export Citation
  • 22.

    Arriagada R, Le Chevalier T, Borie F. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995;87:183190.

    • Search Google Scholar
    • Export Citation
  • 23.

    Auperin A, Arriagada R, Pignon JP. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476484.

    • Search Google Scholar
    • Export Citation
  • 24.

    Slotman B, Faivre-Finn C, Kramer G. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664672.

  • 25.

    Takahashi T, Yamanaka T, Seto T. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:663671.

    • Search Google Scholar
    • Export Citation
  • 26.

    Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist 2009;14:986994.

  • 27.

    Schneider BJ. Management of recurrent small cell lung cancer. J Natl Compr Canc Netw 2008;6:323331.

  • 28.

    Owonikoko TK, Behera M, Chen Z. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 2012;7:866872.

    • Search Google Scholar
    • Export Citation
  • 29.

    von Pawel J, Schiller JH, Shepherd FA. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658667.

    • Search Google Scholar
    • Export Citation
  • 30.

    Eckardt JR, von Pawel J, Pujol JL. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:20862092.

    • Search Google Scholar
    • Export Citation
  • 31.

    O'Brien ME, Ciuleanu TE, Tsekov H. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:54415447.

    • Search Google Scholar
    • Export Citation
  • 32.

    Masters GA, Declerck L, Blanke C. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group trial 1597. J Clin Oncol 2003;21:15501555.

    • Search Google Scholar
    • Export Citation
  • 33.

    Hoang T, Kim K, Jaslowski A. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer 2003;42:97102.

    • Search Google Scholar
    • Export Citation
  • 34.

    van der Lee I, Smit EF, van Putten JW. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 2001;12:557561.

  • 35.

    Johnson DH, Greco FA, Strupp J. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 1990;8:16131617.

    • Search Google Scholar
    • Export Citation
  • 36.

    Masuda N, Fukuoka M, Kusunoki Y. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:12251229.

    • Search Google Scholar
    • Export Citation
  • 37.

    Smit EF, Fokkema E, Biesma B. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998;77:347351.

    • Search Google Scholar
    • Export Citation
  • 38.

    Yamamoto N, Tsurutani J, Yoshimura N. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res 2006;26:777781.

    • Search Google Scholar
    • Export Citation
  • 39.

    Smyth JF, Smith IE, Sessa C. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 1994;30A:10581060.

    • Search Google Scholar
    • Export Citation
  • 40.

    Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993;29A:17201722.

    • Search Google Scholar
    • Export Citation
  • 41.

    Furuse K, Kubota K, Kawahara M. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology 1996;53:169172.

    • Search Google Scholar
    • Export Citation
  • 42.

    Pietanza MC, Kadota K, Huberman K. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 2012;18:11381145.

    • Search Google Scholar
    • Export Citation
  • 43.

    Zauderer MG, Drilon A, Kadota K. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer 2014;86:237240.

    • Search Google Scholar
    • Export Citation
  • 44.

    Hiddinga BI, Pauwels P, Janssens A, van Meerbeeck JP. O(6)-Methylguanine-DNA methyltransferase (MGMT): a drugable target in lung cancer? Lung Cancer 2017;107:9199.

    • Search Google Scholar
    • Export Citation
  • 45.

    Lammers PE, Shyr Y, Li CI. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol 2014;9:559562.

    • Search Google Scholar
    • Export Citation
  • 46.

    Schmittel A, Knodler M, Hortig P. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007;55:109113.

    • Search Google Scholar
    • Export Citation
  • 47.

    Goto K, Ohe Y, Shibata T. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2016;17:11471157.

    • Search Google Scholar
    • Export Citation
  • 48.

    Horn L, Reck M, Spigel DR. The future of immunotherapy in the treatment of small cell lung cancer. Oncologist 2016;21:910921.

  • 49.

    Cooper MR, Alrajhi AM, Durand CR. Role of immune checkpoint inhibitors in small cell lung cancer. Am J Ther 2018;25:e349356.

  • 50.

    Antonia SJ, Lopez-Martin JA, Bendell J. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883895.

    • Search Google Scholar
    • Export Citation
  • 51.

    Hellmann MD, Ott PA, Zugazagoitia J. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): first report of a randomized expansion cohort from CheckMate 032 [abstract]. J Clin Oncol 2017;35(Suppl):Abstract 8503.

    • Search Google Scholar
    • Export Citation
  • 52.

    Hellmann MD, Callahan MK, Awad MM. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 2018;33:853861.e854.

    • Search Google Scholar
    • Export Citation
  • 53.

    Ott PA, Elez E, Hiret S. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol 2017;35:38233829.

    • Search Google Scholar
    • Export Citation
  • 54.

    Chung HC, Lopez-Martin JA, Kao SC. Phase 2 study of pembrolizumab in advanced small-cell lung cancer: KEYNOTE-158 [abstract]. J Clin Oncol 2018;36(Suppl):Abstract 8506.

    • Search Google Scholar
    • Export Citation
  • 55.

    Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther 2017;6:5171.

    • Search Google Scholar
    • Export Citation
  • 56.

    Khunger M, Rakshit S, Pasupuleti V. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 2017;152:271281.

    • Search Google Scholar
    • Export Citation
  • 57.

    Rudin CM, Pietanza MC, Bauer TM. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 2017;18:4251.

    • Search Google Scholar
    • Export Citation
  • 58.

    Carbone DP, Morgensztern D, Le Moulec S. Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: results from the phase 2 TRINITY study [abstract]. J Clin Oncol 2018;36(Suppl):Abstract 8507.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 2 0 0
Full Text Views 5579 3598 286
PDF Downloads 1815 1223 169
EPUB Downloads 0 0 0